MedTrace Logo

Modification Of Disease Outcome In COPD

NCT00158847 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2006-01-20

No results posted yet for this study

Summary

The hypothesis to be tested of this study is that treatment with fluticasone propionate leads to an initial improvement in symptoms, quality of life and lungfunction and a reduction in airways hyperresponsiveness. The continued decline of lungfunction in COPD may not be influenced by longer lasting treatment. Addition of salmeterol will augment the initial benefits of fluticasone without changing the longterm decline in lungfunction.

Conditions

Interventions

DRUG

fluticasone 500 mcg

DRUG

fluticasone 500 mcg + salmeterol 50 mcg

Sponsors & Collaborators

  • Academisch Ziekenhuis Groningen

    collaborator OTHER

  • The Netherlands Asthma Foundation

    collaborator OTHER

  • Netherlands Organisation for Scientific Research

    collaborator OTHER_GOV

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Peter J. Sterk, MD, PhD · Leiden University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Completion
2005-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00158847 on ClinicalTrials.gov